Asher Salmon

992 total citations
28 papers, 723 citations indexed

About

Asher Salmon is a scholar working on Oncology, Epidemiology and Cancer Research. According to data from OpenAlex, Asher Salmon has authored 28 papers receiving a total of 723 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Epidemiology and 7 papers in Cancer Research. Recurrent topics in Asher Salmon's work include Neuroendocrine Tumor Research Advances (7 papers), Neuroblastoma Research and Treatments (5 papers) and Pituitary Gland Disorders and Treatments (5 papers). Asher Salmon is often cited by papers focused on Neuroendocrine Tumor Research Advances (7 papers), Neuroblastoma Research and Treatments (5 papers) and Pituitary Gland Disorders and Treatments (5 papers). Asher Salmon collaborates with scholars based in Israel, Australia and Belgium. Asher Salmon's co-authors include David J. Gross, Merav Fraenkel, Benjamin Gläser, Victoria Doviner, Hermona Soreq, Zafrir Goren, Yodphat Krausz, Nanette Freedman, Eyal Mishani and Roland Chisin and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Biochemical and Biophysical Research Communications.

In The Last Decade

Asher Salmon

28 papers receiving 713 citations

Peers

Countries citing papers authored by Asher Salmon

Since Specialization

Citations

This map shows the geographic impact of Asher Salmon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Asher Salmon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Asher Salmon more than expected).

Fields of papers citing papers by Asher Salmon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Asher Salmon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Asher Salmon. The network helps show where Asher Salmon may publish in the future.

Co-authorship network of co-authors of Asher Salmon

This figure shows the co-authorship network connecting the top 25 collaborators of Asher Salmon. A scholar is included among the top collaborators of Asher Salmon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Asher Salmon. Asher Salmon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center’s 20 years of Experience 2022 ·Journal of the Endocrine Society ·(unknown), Simona Grozinsky‐Glasberg, Kira Oleinikov, David J. Gross, Asher Salmon, Amichay Meirovitz, Ofra Maimon	1
2	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer 2021 ·npj Breast Cancer ·(unknown), Mali Salmon‐Divon, Roberto Salgado, Michael Elkin, Esther Hermano, Ariel M. Rubinstein, Prudence A. Francis, Angelo Di Leo, Giuseppe Viale, Evandro de Azambuja, Lieveke Ameye, Christos Sotiriou, Asher Salmon, Nataly Kravchenko‐Balasha, Amir Sonnenblick	17
3	Reactive stroma and trastuzumab resistance in HER2‐positive early breast cancer 2020 ·International Journal of Cancer ·Amir Sonnenblick, Mali Salmon‐Divon, Roberto Salgado, (unknown), Noam Pondé, (unknown), Asher Salmon, Sibylle Loibl, Carsten Denkert, Heikki Joensuu, Lieveke Ameye, Gert Van den Eynden, Pirkko‐Liisa Kellokumpu‐Lehtinen, Amos Azaria, Sherene Loi, Stefan Michiels, François Richard, Christos Sotiriou	15
4	Beyond the hospital infection control guidelines: a qualitative study using positive deviance to characterize gray areas and to achieve efficacy and clarity in the prevention of healthcare-associated infections 2018 ·Antimicrobial Resistance and Infection Control ·Anat Gesser‐Edelsburg, (unknown), (unknown), (unknown), Peter Vernon van Heerden, Sigal Sviri, Shmuel Benenson, Uriel Trahtemberg, Efrat Orenbuch‐Harroch, Lior Löwenstein, (unknown), Asher Salmon, Allon E. Moses	18
5	Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE 2018 ·EJNMMI Physics ·(unknown), Simona Grozinsky‐Glasberg, David J. Gross, Yodphat Krausz, Asher Salmon, Amichay Meirovitz, Nanette Freedman, (unknown)	13
6	<em>SYK </em>expression level distinguishes control from <em>BRCA1</em>-mutated lymphocytes 2018 ·Cancer Management and Research ·(unknown), Amir Sonnenblick, (unknown), Luna Kadouri, Tamar Peretz, Asher Salmon, Mali Salmon‐Divon	3
7	What variables are associated with the public's willingness to take measures to maintain a hygienic hospital environment? 2018 ·American Journal of Infection Control ·Anat Gesser‐Edelsburg, (unknown), (unknown), Asher Salmon, Lior Löwenstein, (unknown)	2
8	Utilizing fluorescent life time imaging microscopy technology for identify carriers of BRCA2 mutation 2016 ·Biochemical and Biophysical Research Communications ·(unknown), (unknown), (unknown), (unknown), Luna Kaduri, Amir Sonnenblick, Dror Fixler, Asher Salmon, Mali Salmon‐Divon	9
9	VennBLAST—Whole transcriptome comparison and visualization tool 2014 ·Genomics ·(unknown), Gil Stelzer, (unknown), Asher Salmon, Mali Salmon‐Divon	3
10	A phase 1/2 of a combination of Cetuximab and Taxane for “triple negative” breast cancer patients 2014 ·The Breast ·Hovav Nechushtan, Gilad W. Vainer, (unknown), Asher Salmon, Tamar Hamburger, Tamar Peretz	20
11	Everolimus therapy for progressive adrenocortical cancer 2013 ·Endocrine ·Merav Fraenkel, Maria Gueorguiev, (unknown), Asher Salmon, Ashley Grossman, David J. Gross	38
12	Pregnancy in a Patient With Adrenal Carcinoma Treated With Mitotane: A Case Report and Review of Literature 2012 ·The Journal of Clinical Endocrinology & Metabolism ·Liana Tripto‐Shkolnik, Zeev Blumenfeld, Moshe Bronshtein, Asher Salmon, Anat Jaffe	19
13	Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour 2011 ·Clinical Endocrinology ·Roy Eldor, Benjamin Gläser, Merav Fraenkel, Victoria Doviner, Asher Salmon, David J. Gross	74
14	Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center 2010 ·Endocrine ·Auryan Szalat, Merav Fraenkel, Victoria Doviner, Asher Salmon, David J. Gross	46
15	68Ga-DOTA-NOC PET/CT Imaging of Neuroendocrine Tumors: Comparison with 111In-DTPA-Octreotide (OctreoScan®) 2010 ·Molecular Imaging and Biology ·Yodphat Krausz, Nanette Freedman, Rina Rubinstein, (unknown), Marina Orevi, Sagi Tshori, Asher Salmon, Benjamin Gläser, Roland Chisin, Eyal Mishani, David J. Gross	102
16	Metastatic pancreatic neuroendocrine tumor presenting as a pituitary space occupying lesion: a case report 2007 ·Pituitary ·Chamutal Gur, Gadi Lalazar, Asher Salmon, (unknown), David J. Gross	9
17	The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R 2006 ·Endocrine Related Cancer ·David J. Gross, Gabriel Munter, Menachem Bitan, Tali Siegal, Alberto Gabizón, (unknown), Ofer Merimsky, Aliza Ackerstein, Asher Salmon, Avishai Sella, Shimon Slavin, (unknown)	113
18	Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers 2005 ·British Journal of Cancer ·Zsofia Kote‐Jarai, Asher Salmon, (unknown), Michelle Copeland, Audrey Ardern‐Jones, Imogen Locke, Susan Shanley, Brenda Summersgill, Yong‐Jie Lu, Janet Shipley, Rosalind A. Eeles	28
19	Muscarinic modulations of neuronal anticholinesterase responses 2005 ·Chemico-Biological Interactions ·Asher Salmon, Christina Erb, Eran Meshorer, Dalia Ginzberg, (unknown), I. Rabinovitz, G. Amitai, Hermona Soreq	18
20	HUMAN ERYTHROCYTE BUT NOT BRAIN ACETYLCHOLINESTERASE HYDROLYSES HEROIN TO MORPHINE 1999 ·Clinical and Experimental Pharmacology and Physiology ·Asher Salmon, Zafrir Goren, (unknown), Hermona Soreq	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact